Amgen (AMGN) announced positive results from the Phase 3 OASIZ-301 study of dazodalibep

• Both dazodalibep dosing regimens met the primary endpoint at Week 48, demonstrating statistically significant reductions in systemic disease activity compared with placebo, as measured by the ESSDAI score.

Positive late-stage readouts for a novel mechanism in an indication with no approved systemic therapy have historically carried more weight than the average Phase 3 print, since first-in-class success in an autoimmune indication with unmet need opens a regulatory path rather than merely expanding a label. The relevant precedent pattern is that both dosing arms hitting the primary endpoint removes dose-selection ambiguity ahead of filing, which in comparable episodes has shortened the time to submission and reduced the binary risk around a second pivotal. Amgen has prior form in converting immunology assets acquired through deals into filings, so the follow-on sequence to watch is the full data presentation at a medical meeting, regulatory engagement on a filing timeline, and any safety signal in the longer-term extension that trial summaries of this kind tend not to capture. The distinction worth drawing is between statistical significance on the endpoint measure and the magnitude of clinical benefit, since payers and regulators in this space have historically focused on effect size and durability rather than the p-value alone. As a single-bullet headline, the detail is thin and the fuller data set is the real catalyst.